1. Home
  2. KLRS vs TGHL Comparison

KLRS vs TGHL Comparison

Compare KLRS & TGHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KLRS
  • TGHL
  • Stock Information
  • Founded
  • KLRS 2019
  • TGHL 2020
  • Country
  • KLRS United States
  • TGHL Singapore
  • Employees
  • KLRS N/A
  • TGHL N/A
  • Industry
  • KLRS Biotechnology: Biological Products (No Diagnostic Substances)
  • TGHL EDP Services
  • Sector
  • KLRS Health Care
  • TGHL Technology
  • Exchange
  • KLRS Nasdaq
  • TGHL Nasdaq
  • Market Cap
  • KLRS 46.0M
  • TGHL 42.0M
  • IPO Year
  • KLRS N/A
  • TGHL 2025
  • Fundamental
  • Price
  • KLRS $4.78
  • TGHL $0.59
  • Analyst Decision
  • KLRS Strong Buy
  • TGHL
  • Analyst Count
  • KLRS 3
  • TGHL 0
  • Target Price
  • KLRS $21.50
  • TGHL N/A
  • AVG Volume (30 Days)
  • KLRS 107.9K
  • TGHL 477.8K
  • Earning Date
  • KLRS 11-13-2025
  • TGHL 05-01-2026
  • Dividend Yield
  • KLRS N/A
  • TGHL N/A
  • EPS Growth
  • KLRS N/A
  • TGHL N/A
  • EPS
  • KLRS N/A
  • TGHL N/A
  • Revenue
  • KLRS N/A
  • TGHL $173,668.00
  • Revenue This Year
  • KLRS N/A
  • TGHL N/A
  • Revenue Next Year
  • KLRS N/A
  • TGHL N/A
  • P/E Ratio
  • KLRS N/A
  • TGHL N/A
  • Revenue Growth
  • KLRS N/A
  • TGHL 84.40
  • 52 Week Low
  • KLRS $2.14
  • TGHL $0.53
  • 52 Week High
  • KLRS $23.69
  • TGHL $4.25
  • Technical
  • Relative Strength Index (RSI)
  • KLRS 47.17
  • TGHL N/A
  • Support Level
  • KLRS $4.67
  • TGHL N/A
  • Resistance Level
  • KLRS $5.10
  • TGHL N/A
  • Average True Range (ATR)
  • KLRS 0.41
  • TGHL 0.00
  • MACD
  • KLRS -0.03
  • TGHL 0.00
  • Stochastic Oscillator
  • KLRS 39.41
  • TGHL 0.00

About KLRS Kalaris Therapeutics Inc. Common Stock

Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.

About TGHL The GrowHub Limited Class A Ordinary Shares

The Growhub Ltd operates at the intersection of technology and supply chain management in the food industry, focusing on enhancing product traceability and authenticity. With a commitment to innovation and sustainability, It has developed a multi-faceted approach to address industry challenges. its business currently comprises two main divisions, which are the GrowHub Platform and its product trading facilitation offering.

Share on Social Networks: